← Eichor
Study identifier: NCT06015776 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Purinergic Signaling and the Postmenopausal Heart

Condition: Diastolic Heart Failure · Heart Failure With Preserved Ejection Fraction  ·  Sponsor: Beth Israel Deaconess Medical Center

PhaseN/A
Planned participants500
Who can joinAll sexes, 30 Years to 88 Years
Healthy volunteersNo

About this study

There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.

This description comes directly from the study's public registry record.

Talk to the study team

Robina Matyal, MD  ·  6176401208  ·  rmatyal1@bidmc.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Beth Israel Deaconess Medical CenterBoston, Massachusetts, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06015776